Who are CONVENTIONAL ABVD's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Consolidation Chemotherapy, chemotherapy of mFOLFOX6 or FOLFIRI, Dose dense AC followed by T + trastuzumab, Adjuvant chemotherapy, FEC, PTH followed by dose dense AC of FEC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/conventional-abvd.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CONVENTIONAL ABVD — Competitive Intelligence Brief

CONVENTIONAL ABVD (CONVENTIONAL ABVD) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy regimen. Area: Oncology.

phase 2 chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CONVENTIONAL ABVD (CONVENTIONAL ABVD) — Ospedale Santa Croce-Carle Cuneo. This chemotherapy regimen combines Adriamycin, Bleomycin, Vinblastine, and Dacarbazine to target rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CONVENTIONAL ABVD TARGET	CONVENTIONAL ABVD	Ospedale Santa Croce-Carle Cuneo	phase 2	chemotherapy regimen
Consolidation Chemotherapy	Consolidation Chemotherapy	National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos	marketed	Combination chemotherapy regimen
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
Adjuvant chemotherapy	Adjuvant chemotherapy	Institut de Cancérologie de Lorraine	marketed	Chemotherapy regimen (multi-agent or single-agent cytotoxic)
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy regimen class)

University Hospital, Grenoble · 2 drugs in this class
Canadian Cancer Trials Group · 1 drug in this class
Centre Georges Francois Leclerc · 1 drug in this class
Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. · 1 drug in this class
French Innovative Leukemia Organisation · 1 drug in this class
AIO-Studien-gGmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
National Research Center for Hematology, Russia · 1 drug in this class
Ospedale Santa Croce-Carle Cuneo · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CONVENTIONAL ABVD — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-abvd. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab